STOCK TITAN
  1. Home
  2. Sec-filings
  3. CORT
  4. [Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity

Corcept insider option exercise and same‑day sale totaling 5,000 shares

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Corcept Therapeutics (CORT) insider transaction: On 10/01/2025, an officer exercised 5,000 stock options at an exercise price of $13.56 per share and acquired 5,000 common shares. The same day, the officer sold a total of 5,000 shares in three trades executed under a Rule 10b5-1 plan adopted on August 30, 2024: 927 shares at $83.7111, 3,473 shares at $84.9217, and 600 shares at $85.3875.

Following these transactions, the officer beneficially owned 10,277 common shares. Footnotes state this figure includes unvested restricted stock awards granted on December 2, 2024; March 3, 2025; June 2, 2025; and September 2, 2025, which vest one year from their grant dates if conditions are met. The officer also held 21,571 derivative securities (stock options) after the reported activity, with the exercised option series expiring on 02/07/2030.

Positive

  • None.

Negative

  • None.
Insider Lyon Joseph Douglas
Role See Remarks
Sold 5,000 shs ($424K)
Type Security Shares Price Value
Exercise Stock option (right to buy) 5,000 $0.00 --
Exercise Common Stock 5,000 $13.56 $68K
Sale Common Stock 927 $83.7111 $78K
Sale Common Stock 3,473 $84.9217 $295K
Sale Common Stock 600 $85.3875 $51K
Holdings After Transaction: Stock option (right to buy) — 21,571 shares (Direct); Common Stock — 15,277 shares (Direct)
Footnotes (1)
  1. Includes 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $83.23 to $84.195 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $84.26 to $85.25 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $85.265 to $85.48 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Fully exercisable.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lyon Joseph Douglas
(Last) (First) (Middle)
C/O CORCEPT THERAPEUTICS INCORPORATED
101 REDWOOD SHORES PARKWAY
(Street)
REDWOOD CITY CA 94065
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/01/2025 M 5,000 A $13.56 15,277(1) D
Common Stock 10/01/2025 S(2) 927 D $83.7111(3) 14,350(1) D
Common Stock 10/01/2025 S(2) 3,473 D $84.9217(4) 10,877(1) D
Common Stock 10/01/2025 S(2) 600 D $85.3875(5) 10,277(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock option (right to buy) $13.56 10/01/2025 M 5,000 (6) 02/07/2030 Common Stock 5,000 $0 21,571 D
Explanation of Responses:
1. Includes 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 749 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
2. The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on August 30, 2024 in effect at the time of this transaction.
3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $83.23 to $84.195 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $84.26 to $85.25 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $85.265 to $85.48 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
6. Fully exercisable.
Remarks:
Chief Accounting & Technology Officer
/s/ Joseph Douglas Lyon 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did CORT's officer do on 10/01/2025?

Exercised 5,000 stock options at $13.56 per share and sold a total of 5,000 common shares in three trades.

At what prices were CORT shares sold?

Sales were executed at weighted average prices of $83.7111, $84.9217, and $85.3875 per share.

How many CORT shares did the officer own after the transactions?

The officer beneficially owned 10,277 common shares after the reported transactions.

Was this trading under a Rule 10b5-1 plan?

Yes. The transactions were made pursuant to a Rule 10b5-1 plan adopted on August 30, 2024.

What derivative holdings remained after the transactions?

The officer held 21,571 derivative securities (stock options) following the reported activity.

What is the status of unvested restricted stock awards?

Beneficial ownership includes awards granted on Dec 2, 2024, Mar 3, 2025, Jun 2, 2025, and Sep 2, 2025, vesting one year from grant if conditions are met.

When do the exercised options expire?

The exercised option series has an expiration date of 02/07/2030.